Sugi Predict

Sugi Predict / Compounds / SCHEMBL4892277

SCHEMBL4892277

SCHEMBL4892277

CC(C)(C)OC(=O)n1cc(CCBr)c2ccccc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.65
▸ HTR6 P50406 1/20 0.53
▸ EPHX1 P07099 1/20 0.53
▸ PDE10A Q9Y233 1/20 0.52
▸ ADAM17 P78536 1/20 0.44
▸ ACHE P22303 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ MARK3 P27448 1/20 0.43
▸ MAP4K2 Q12851 1/20 0.43
▸ CAMK2B Q13554 1/20 0.43
▸ PIM3 Q86V86 1/20 0.43
▸ PIM2 Q9P1W9 1/20 0.43
▸ CHRM2 P08172 1/20 0.42
▸ CHRM4 P08173 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ CREBBP Q92793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30859622 1.00 L3MBTL1 (0.65) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL29504836 0.89 L3MBTL1 (0.67) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL1483546 0.89 L3MBTL1 (0.67) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL30721514 0.88 L3MBTL1 (0.66) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL22651784 0.88 L3MBTL1 (0.70) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL4109142 0.88 L3MBTL1 (0.66) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL12050578 0.87 L3MBTL1 (0.65) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL7505969 0.87 L3MBTL1 (0.65) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL29992401 0.87 L3MBTL1 (0.65) L3MBTL1HTR6EPHX1PDE10AADAM17
SCHEMBL10088115 0.86 L3MBTL1 (0.74) L3MBTL1HTR6EPHX1PDE10AADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117486929-A Substituted alkyl germanium compound and modularized synthesis method thereof 西安交通大学 2024-02-02 — — CN claimed
CN-117486929-A Substituted alkyl germanium compound and modularized synthesis method thereof 西安交通大学 2024-02-02 — — CN disclosed
EP-3524324-A1 HISTONE DEACETYLASE INHIBITORS BioMarin Pharmaceutical Inc. (US) 2019-08-14 — — EP disclosed
CN-105722831-B Pyridazinone compound and application thereof 艾丽奥斯生物制药有限公司 2019-08-06 — — CN disclosed
US-10364226-B2 Pyridazinone compounds and uses thereof ALIOS BIOPHARMA, INC. (US) 2019-07-30 — — US disclosed
EP-3030549-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF ALIOS BIOPHARMA INC (US) 2019-02-20 — — EP disclosed
US-20180208606-A1 HISTONE DEACETYLASE INHIBITORS REPLIGEN CORPORATION 2018-07-26 — — US disclosed
US-9908899-B2 Histone deacetylase inhibitors BIOMARIN PHARMACEUTICAL INC. (US) 2018-03-06 — — US disclosed
US-20170050984-A1 HISTONE DEACETYLASE INHIBITORS REPLIGEN CORPORATION 2017-02-23 — — US disclosed
US-20170050984-A1 HISTONE DEACETYLASE INHIBITORS REPLIGEN CORPORATION 2017-02-23 — — US disclosed
WO-2005094810-A2 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2005-10-13 — — WO disclosed
US-20050171104-A1 Novel thyroid receptor ligands KARO BIO AB (SE) 2005-08-04 — — US disclosed
EP-1549309-A2 SOMATOSTATIN ANALOGUE COMPOUNDS ChemBridge Research Laboratories, Inc. (US) 2005-07-06 — — EP disclosed
US-6872827-B2 Somatostatin analogue compounds CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) 2005-03-29 — — US disclosed
EP-1492756-A1 NOVEL THYROID RECEPTOR LIGANDS KARO BIO AB (SE) 2005-01-05 — — EP disclosed
US-20040019069-A1 Somatostatin analogue compounds CHEMBRIDGE CORPORATION 2004-01-29 — — US disclosed
WO-2003090677-A2 SOMATOSTATIN ANALOGUE COMPOUNDS CHEMBRIDGE RESEARCH LAB., LLC (US) 2003-11-06 — — WO disclosed
WO-2003084915-A1 NOVEL THYROID RECEPTOR LIGANDS KARO BIO AB (SE) 2003-10-16 — — WO disclosed
US-5238938-A Nephrosis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-08-24 — — US disclosed
EP-0411150-A1 INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208606-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC2, HDAC3 L3MBTL1 448/4885HTR6 3184/4885EPHX1 4028/4885
US-10364226-B2 Pyridazinone compounds and uses thereof PDXK, PNPO, PLPBP L3MBTL1 3874/4885HTR6 888/4885EPHX1 1038/4885
US-20170050984-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC2, HDAC3 L3MBTL1 448/4885HTR6 3184/4885EPHX1 4028/4885
US-20050171104-A1 Novel thyroid receptor ligands TSHR, THRB, THRA L3MBTL1 851/4885HTR6 1247/4885EPHX1 1849/4885
US-20040019069-A1 Somatostatin analogue compounds SSTR2, SSTR1, SSTR4 L3MBTL1 3630/4885HTR6 213/4885EPHX1 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.